Corcept Therapeutics Incorporated (CORT)
- Previous Close
22.30 - Open
22.76 - Bid 22.92 x 100
- Ask 23.03 x 100
- Day's Range
22.36 - 24.23 - 52 Week Range
20.84 - 34.28 - Volume
1,866,689 - Avg. Volume
1,190,456 - Market Cap (intraday)
2.388B - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
24.47 - EPS (TTM)
0.94 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
42.80
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
www.corcept.comRecent News: CORT
Performance Overview: CORT
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CORT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CORT
Valuation Measures
Market Cap
2.39B
Enterprise Value
2.02B
Trailing P/E
24.47
Forward P/E
149.25
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.33
Price/Book (mrq)
4.71
Enterprise Value/Revenue
4.19
Enterprise Value/EBITDA
18.42
Financial Highlights
Profitability and Income Statement
Profit Margin
22.00%
Return on Assets (ttm)
11.13%
Return on Equity (ttm)
21.05%
Revenue (ttm)
482.38M
Net Income Avi to Common (ttm)
105.5M
Diluted EPS (ttm)
0.94
Balance Sheet and Cash Flow
Total Cash (mrq)
368.22M
Total Debt/Equity (mrq)
0.03%
Levered Free Cash Flow (ttm)
128.39M
Research Analysis: CORT
Company Insights: CORT
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: CORT
CORT: Lowering target price to $19.00
CORCEPT THERAPEUTICS INC has an Investment Rating of SELL; a target price of $19.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetCORT: What does Argus have to say about CORT?
CORCEPT THERAPEUTICS INC has an Investment Rating of SELL; a target price of $20.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetCORT: Lowering target price to $20.00
CORCEPT THERAPEUTICS INC has an Investment Rating of SELL; a target price of $20.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetCORT: Rating decreased to a SELL
CORCEPT THERAPEUTICS INC has an Investment Rating of SELL; a target price of $26.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice Target